



Dear USC Faculty and Staff,

USC Stevens is pleased to share with you that USC and Amgen have entered into a three-year Master Research Collaboration Agreement focused on pre-clinical research proposals. Included below is the formal announcement for you to share with your research colleagues at USC.

USC Stevens will be scheduling an informational meeting at the Health Science Campus and University Park Campus within the next couple of weeks to enable an open discussion about the nature of the collaboration and the process for submitting research proposals.

Best regards,

Vasiliki Anest
Senior Director, Corporate Collaborations and Strategic Alliances
USC Stevens Center for Innovation

Amgen enters into master research collaboration agreement with USC

Amgen recently entered into a three-year master research collaboration with the University of Southern California. The agreement consists of a set of pre-defined terms and conditions in order to facilitate and streamline early discovery and translational preclinical research collaborations. It supports Amgen and USC's shared interest in advancing basic biology discovery and strengthening relationships between academia and industry.

"Going back to its early days, Amgen has had a strong relationship with USC as a result of its close proximity, talented researchers and advanced research facilities," said David Reese, senior vice president of Translational Research. "There have been a variety of collaborations between the two organizations over the years, which Amgen and USC expect to continue. This is why we created this master agreement."

"We look forward to continuing our relationship with Amgen and developing a longer term strategic collaboration integrating the expertise of USC biomedical research with the R&D capabilities of Amgen," said Randolph Hall, Vice President of Research at USC. "Our collaboration with Amgen is aligned with our commitment to advancing biomedical research in Los Angeles."

This master agreement was established to streamline the process for executing pre-clinical collaborations, with the goal of facilitating the rapid prosecution of important research projects.



Submission and approval process

To submit a scope of work (SOW) request form, please contact USC Stevens Corporate Collaborations, Vasiliki Anest at anest@usc.edu. Scientific and budget approval must be obtained prior to submission of the SOW.

FAQs

What is a Master Research Collaboration Agreement?

Master RCAs, sometimes called "blanket" or "umbrella" agreements, are used when a company expects to fund multiple projects with USC over a long period of time. In such cases, the legal terms and conditions of the agreement are prenegotiated. Once a Master Agreement is in place, an "addendum" is generated for each new scope of work to be done under the Master Agreement. The Addendum sets forth the items particular to a Scope of Work (SOW) such as dollar amount, project details, and principal investigator. These Addenda are "attached" to the Master Agreement. This streamlines the process and alleviates the need to negotiate the main terms of the agreement, as the majority of the terms are agreed upon and only the particulars within an SOW need to be negotiated.

Who is eligible to apply? What are the deadlines to submit?

All researchers and clinicians are invited to apply with proposals focused on preclinical (early/translational research). This is an open call and an unlimited number of proposals are permitted.

What is the amount of funding?

The amount of funding is determined by Amgen with consideration given to staffing the research project and material needed during the performance of the SOW.

How do I obtain the SOW form and what information is required?

Contact USC Stevens at anest@usc.edu to obtain the Scope Of Work (SOW) form. Scientific and budget approval must be obtained prior to submission of the SOW.

With this Master RCA, all the project-specific information is combined into an addendum. The addendum will contain a scope of work (SOW) form that is pre-approved by Amgen and USC, into which a principal investigator inserts the full information required for Amgen to review, accept, and award the proposal. An addendum frequently contains the following:

- Scope of work to be conducted and associated budget
- Payment obligations and timing
- Management of the research project



- Staffing of the research project
- Schedules, milestones, and deliverables
- Co-funding information (if any)
- Background intellectual property information (if any)

Does USC have other research relationships with Amgen?

Yes. USC has executed sponsored research agreements with Amgen on individual projects.

USC Stevens has executed a Master Material Transfer Agreement relating to the Amgen Biology Enabling Resource (AmBER) catalog, which includes small molecules, peptides, cells, proteins and hybridomas. To obtain a copy of the list of currently available materials, contact USC Stevens at AmBER@stevens.usc.edu. These materials will be available for internal research use only by USC investigators, and not for redistribution.